Mirum Pharmaceuticals price target raised to $140 from $95 at Citizens

Citizens analyst Jonathan Wolleben raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $140 from $95 and keeps an Outperform rating on the shares. Mirum has outperformed year to date and is expected to continue leading in 2026, supported by multiple high-confidence pivotal readouts across its pipeline, the analyst tells investors in a research note. The brelovitug acquisition adds a late-stage asset with near-term data, while volixibat’s pivotal readout in 2Q26 for primary sclerosing cholangitis drives increased confidence and a higher probability of success, the firm says.